Seres Therapeutics Inc expected to post a loss of $2.18 a share - Earnings Preview

Seres Therapeutics

31/07/2026 13:58

Seres Therapeutics Inc MCRB.OQ MCRB.O is expected to  show a rise in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2026
The Cambridge Massachusetts-based  company is expected to report revenue of $179 thousand, according to the mean estimate from 2 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Seres Therapeutics Inc is for a loss of $2.18 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Seres Therapeutics Inc is $17.00, about 255.6% above its last closing price of $4.78
This summary was machine generated July 31 at 12:58 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)